Compare AHRT & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AHRT | ALT |
|---|---|---|
| Founded | 1979 | 1997 |
| Country | United States | United States |
| Employees | 98 | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 455.6M | 421.5M |
| IPO Year | 2013 | 2005 |
| Metric | AHRT | ALT |
|---|---|---|
| Price | $6.48 | $3.09 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $7.00 | ★ $17.67 |
| AVG Volume (30 Days) | 620.4K | ★ 5.0M |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | ★ 9.30% | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | $854.92 | N/A |
| Revenue Next Year | $11.36 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $5.13 | $2.56 |
| 52 Week High | $6.50 | $7.73 |
| Indicator | AHRT | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 65.90 | 47.28 |
| Support Level | $5.93 | $2.87 |
| Resistance Level | N/A | $4.23 |
| Average True Range (ATR) | 0.16 | 0.18 |
| MACD | 0.04 | 0.04 |
| Stochastic Oscillator | 98.28 | 53.68 |
AH Realty Trust Inc is a real estate investment trust (REIT). It owns, operates, and acquires high-quality properties across the Mid-Atlantic and Southeast, creating lasting value for investors, partners, clients, tenants, and communities. The group focuses on operating and acquiring high-quality, well-positioned assets with growth potential and delivering long-term value for shareholders. Its portfolio includes Harbor Point, Southern Post, The Interlock, and Others.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.